KVUE - Kenvue - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025
Health Supplements, Skin Care, Personal Care, Baby Care, Oral Care
Kenvue Inc. is a global consumer health company that operates through three distinct business segments: Self Care, Skin Health and Beauty, and Essential Health.
The Self Care segment is dedicated to providing a range of over-the-counter (OTC) products that cater to various health needs. This includes cough, cold, and allergy remedies, pain relief medications, digestive health products, smoking cessation aids, eye care solutions, and other essential health products. Some of the well-known brands under this segment include Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec.
The Skin Health and Beauty segment focuses on providing a diverse range of personal care products that promote healthy skin and beauty. This includes face and body care products, hair care solutions, sun care products, and other personal care items. The segment boasts a portfolio of popular brands such as Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX.
The Essential Health segment is responsible for offering a variety of health and hygiene products that cater to different consumer needs. This includes oral care products, baby care items, women's health products, wound care solutions, and other essential health products. Some of the notable brands under this segment include Listerine, Johnson's, Band-Aid, Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash.
Kenvue Inc. was established in 2022 and is headquartered in Skillman, New Jersey. For more information about the company and its products, visit their official website at https://www.kenvue.com.
Drawdown (Underwater) Chart
KVUE Stock Overview
Market Cap in USD | 41,502m |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
GiC SubIndustry | Personal Care Products |
TER | 0.00% |
IPO / Inception | 2023-05-04 |
KVUE Stock Ratings
Growth 5y | -25.0 |
Fundamental | 22.3 |
Dividend | 46.6 |
Rel. Performance vs Sector | 0.43 |
Analysts | 3.56/5 |
Fair Price Momentum | 25.22 USD |
Fair Price DCF | 23.92 USD |
KVUE Dividends
Dividend Yield 12m | 3.49% |
Yield on Cost 5y | 3.14% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 100.0% |
KVUE Growth Ratios
Growth 12m | 11.35% |
Growth Correlation 12m | -2% |
Growth Correlation 3m | 81% |
CAGR 5y | -7.33% |
CAGR/Mean DD 5y | -0.35 |
Sharpe Ratio 12m | 0.22 |
Alpha vs SP500 12m | -1.76 |
Beta vs SP500 5y weekly | 0.39 |
ValueRay RSI | 97.38 |
Volatility GJR Garch 1y | 24.64% |
Price / SMA 50 | 15.28% |
Price / SMA 200 | 17.39% |
Current Volume | 12941.5k |
Average Volume 20d | 13070.5k |
External Links for KVUE Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of September 12, 2024, the stock is trading at USD 23.09 with a total of 12,941,467 shares traded.
Over the past week, the price has changed by +2.58%, over one month by +10.55%, over three months by +26.23% and over the past year by +10.64%.
According to ValueRays Forecast Model, KVUE Kenvue will be worth about 27.4 in September 2025. The stock is currently trading at 23.09. This means that the stock has a potential upside of +18.84%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.1 | -4.42 |
Analysts Target Price | 26.7 | 15.6 |
ValueRay Target Price | 27.4 | 18.8 |